Home › Funds › FAYEZ SAROFIM & CO › ABT

FAYEZ SAROFIM & CO position in ABT

ABBOTT LABORATORIES · Health Care

FAYEZ SAROFIM & CO reported holding 1,635,447 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$161.6M, representing 0.39% of its reported portfolio and ranking #50 among its reported holdings. FAYEZ SAROFIM & CO has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.64M sh
Reported value held$161.62M
Portfolio Weight0.39%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How FAYEZ SAROFIM & CO's ABT position evolved

FAYEZ SAROFIM & CO first disclosed a stake in ABT in Q3 2023 at 4,301,336 shares (US$416.6M). The position peaked in Q2 2025 at 4,522,297 shares, worth US$619.1M. Across 13 filings, FAYEZ SAROFIM & CO increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,635,447 shares valued at US$161.6M — a reduction of -1,642,867 shares quarter over quarter.. Notable position changes include a 50% trim in Q3 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.30M $416.58M New
Q4 2023 4.03M $450.84M Reduce
Q1 2024 4.03M $457.97M Hold
Q2 2024 4.13M $429.22M Add
Q3 2024 4.19M $477.68M Add
Q4 2024 4.68M $532.86M Add
Q1 2025 4.62M $617.71M Reduce
Q2 2025 4.52M $619.11M Reduce
Q3 2025 4.52M $609.16M Hold
Q4 2025 4.48M $561.36M Reduce
Q1 2026 4.28M $439.65M Reduce
Q2 2026 3.28M $297.47M Reduce
Q3 2026 1.64M $161.62M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has FAYEZ SAROFIM & CO held ABT?

FAYEZ SAROFIM & CO has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is FAYEZ SAROFIM & CO's current position in ABT?

As of Q3 2026, FAYEZ SAROFIM & CO holds 1.64M shares of ABT (ABBOTT LABORATORIES), valued at $161.62M, representing 0.39% of its reported portfolio and ranking #50.

Has FAYEZ SAROFIM & CO been buying or selling ABT?

In the latest 13F filing (Q3 2026), FAYEZ SAROFIM & CO reduced its position in ABT. The position peaked in Q2 2025 at 4.52M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.